Floatz logo

Muromonab-Cd3

Juvenile Myelomonocytic Leukemia

St. Jude Children's Research Hospitalmonoclonal_antibodyPhase 3Dormant
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
89/ 100

Competitive context

21 Active assets in the Juvenile Myelomonocytic Leukemia cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Masonic Cancer Center, University of Minnesota
Phase 4BBB
Busulphan
Masonic Cancer Center, University of Minnesota
Phase 4BBB
Monomethyl Fumarate
Masonic Cancer Center, University of Minnesota
Phase 2BB
Fludarabine
Children's Oncology Group
Phase 3BB
CYCLOSPORIN A
Case Comprehensive Cancer Center
Phase 3BB

View all 36 →

Same molecule, other indications

Muromonab-Cd3 is also rated in:

acute lymphoblastic leukemiaDormant
BB
Indicative ·
69 / 100
View asset →
Myelodysplastic Syndrome (MDS)Dormant
BB
Indicative ·
69 / 100
View asset →
paroxysmal nocturnal hemoglobinuriaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →